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Abstract Valproate is an effective anti-epileptic and mood
stabilizer drug, but its prescription may be complicated by
the development of thrombocytopenia. The purpose of the
present manuscript is to provide a critical overview about
the risk of thrombocytopenia during treatment with val-
proate. A search of the main database sources has been
conducted to identify relevant papers about the topic. In the
studies with a larger sample size ([150 subjects), throm-
bocytopenia occurred in 12–18% of subjects receiving
treatment with valproate. Advanced age, female gender,
and high doses were found to be risk factors for the
development of thrombocytopenia during treatment with
valproate. Future research is needed to clarify the clinical
impact of the occurrence of thrombocytopenia during val-
proate treatment (e.g., the risk of life-threatening events
such as stroke or the development of thrombocytopenia
during short- versus long-term administration, or oral ver-
sus intravenous formulations).
Key Points
Treatment with valproic acid (VPA), despite its
efficacy in bipolar disorder and epilepsy, may be
associated with thrombocytopenia.
The risk factors for VPA-associated
thrombocytopenia include female gender, advanced
age, and high doses.
Future research should define the clinical impact of
VPA-associated thrombocytopenia (e.g., the risk of
hemorrhagic stroke during VPA treatment).
1 Introduction
Valproic acid (VPA) was synthesized by the American
chemist Beverly S. Burton more than a century ago as a
derivative of valeric acid, a component of the herbal
medicine Valeriana officinalis. It was mainly used as a
solvent for organic compounds until 1963, when Pierre
Eymard discovered that all solutions containing valproate
had anticonvulsant properties [1]. Rapidly, VPA came into
regular clinical usage in France (late 1960s) as well as in
the UK (1972) and the US (1978). Currently, VPA is
widely prescribed as an antiepileptic drug and mood sta-
bilizer. Its effectiveness in bipolar disorder (BD) was firstly
demonstrated by Lambert and colleagues in 1966 [1], and
now international guidelines recommend its use for acute
and long-term treatment of BD [2]. Of note, VPA
monotherapy has showed the same effectiveness as lithium
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and atypical antipsychotics for the treatment of acute
mania, but with a better tolerability [2]. VPA can be cur-
rently considered as the first-line option for almost all
epileptic syndromes (focal seizures with or without sec-
ondary generalization), including childhood ones.
Despite its long-standing usage, the mechanism of
action of VPA is still debated. Studies originally focused
on its ability to dampen neuronal hyper-excitability by
potentiating the inhibition of neurotransmission, as a result
of its chemical similarity to gamma-aminobutyric acid
(GABA). More recently, some research has shown further
pharmacodynamic properties of the compound, including a
direct effect on voltage-gated sodium channels or the dis-
ruption of the membrane environment of sodium channels
[3]. VPA also appears to regulate the excitatory activity of
NMDA glutamate receptors and modulates the epigenetic
regulation of neuronal gene expression by non-selective
inhibition of histone deacetylase [1].
Common side effects of VPA include fatigue, tremor,
sedation, gastrointestinal symptoms, and weight gain; these
side effects are mostly dose or serum concentration
dependent and can be minimized by dosage modification.
The teratogenic risks of the compound are well docu-
mented in the literature. VPA adverse reactions can be
classified as neurological, metabolic, endocrine, and
hematological ones. We decided to focus on thrombocy-
topenia because this side effect often goes unnoticed and
can suddenly manifest with life-threatening events such as
hemorrhagic stroke [4]. The purpose of the present manu-
script is therefore to provide a critical overview about the
risk of thrombocytopenia in subjects treated with VPA. To
our knowledge, there are no recent comprehensive reviews
about this specific topic. From a statistical point of view,
thrombocytopenia is defined as a platelet count of
\150,000 per microliter (the 2.5th lower percentile);
however, emergency treatment is required in case of a
count \50,000 per microliter. In some research, a more
restricted definition of thrombocytopenia is used: a platelet
count of\100,000 or 130,000 per microliter.
2 Methods
A careful search of articles on MEDLINE, PsycINFO, Isi
Web of Knowledge, and Medscape was performed by
matching the words ‘valproate’ and ‘valproic acid’ with
‘thrombocytopenia’. After excluding duplicates, 159
abstracts were screened. Nine papers were finally consid-
ered after excluding off-topic research (e.g., about VPA
efficacy on mood symptoms or epilepsy), case reports and
case series, and articles with pediatric populations. Chil-
dren were excluded because they are thought to have a
different risk of thrombocytopenia as a consequence of
pharmacological treatment [5]. Only papers from the last
30 years (1987–2017) were included as available infor-
mation was not always accurate in most of the previous
articles.
3 Results
It is currently known that thrombocytopenia can occur in
5–18% of patients taking VPA [6, 7], and is more fre-
quently observed in women and elderly subjects [8–10].
Moreover, a lower baseline platelet count is reported to be
an additional risk factor for thrombocytopenia, and VPA
dose influences the final platelet count in a proportional
way [11–13].
The exact mechanism through which valproate can
cause thrombocytopenia is unknown; it can be caused by
an increased disruption of platelets as well as by the for-
mation of autoantibodies destroying platelets or by
decreased production due to a direct toxic effect on bone
marrow [3]. Laboratory studies have shown that VPA
perturbs hematopoietic homeostasis through erythroid dif-
ferentiation inhibition and activation of the myelo-mono-
cytic pathway [3]. The most frequent clinical
manifestations of thrombocytopenia are represented by
prolonged bleeding time, abnormality in laboratory platelet
tests, or petechial bleeding [3].
In a sample of epileptic subjects, May and Sunder [14]
reported thrombocytopenia to be the most frequent adverse
event; nevertheless, hematologic toxicity was never severe
enough to discontinue therapy and it always improved after
small decrements of VPA doses. In Italy, a survey on the
safety profile of antiepileptic drugs reported that the
highest percentage of hematological reactions (including
thrombocytopenia) was related to VPA [15]. A study with a
sample of 126 adult psychiatric patients reported a 5%
prevalence of thrombocytopenia (\150,000/lL) with a
significant increased risk in female subjects in case of
serum concentrations[80 lg/mL; moreover, every 10 lg/
mL increase in serum drug levels was associated with a
decrease of 17 units/lL in the platelet count [6]. Another
survey with 264 psychiatric patients reported a 12%
prevalence of thrombocytopenia, with the elderly having
the highest risk, especially with a VPA dosage [1 g/day
[9]. Trannel and colleagues [8] confirmed in a small sample
of 39 psychiatric patients that elderly patients experienced
thrombocytopenia more frequently than younger ones
during VPA treatment (54 vs 13%). In addition, Nasreddine
and Beydoun [10] reported that about 17.7% of epileptic
patients experience at least one episode of thrombocy-
topenia during VPA treatment, and the risk was signifi-
cantly increased in case of VPA plasma levels [100 lg/
mL for women and 130 lg/mL for men. Finally, a recent
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Table 1 Valproic acid monotherapy and thrombocytopenia: summary of findings
Authors Quality
rating
Sample
size
Study design Disorder Primary objective Valproate
plasma level
(lg/mL)
Rate of
thrombocytopenia
(\150,000/lL)
May and Sunder [14] 2 60 Prospective study.
Hematologists were
blinded with respect
to patients’ treatment
Epilepsy Rate of hematologic
side effects during
VPA treatment
30–145 20%
(thrombocytopenia
\130,000/lL)
Gidal et al. [11] 2 27 Prospective, controlled
study
Epilepsy Rate of
thrombocytopenia
during VPA
treatment
NA NA
Conley et al. [9]a 3 264 Retrospective Psychiatric
patients
Prevalence of
thrombocytopenia in
hospitalized patients
receiving VPA
NA 12%
Trannel et al. [8] 3 39 Retrospective Psychiatric
inpatients
Prevalence of
thrombocytopenia in
hospitalized patients
receiving VPA
16–161 28% (total sample)
54% (elderly
patients)
(thrombocytopenia
\100,000/lL)
De Berardis et al. [13] 2 25 Prospective, controlled
study
New onset
bipolar
patients
Rate of
thrombocytopenia
during VPA
treatment
61b 0%d
Nasreddine and
Beydoun [10]
1 265 Double-blind,
multicenter,
prospective study
Refractory
partial
epilepsy
The evaluation of the
relationship between
VPA plasma levels
and platelet counts
13–257
Increased risk
[100 for
women and
[130 for
men
18%
(thrombocytopenia
\100,000/lL)
Vasudev et al. [6] (no
information about
concomitant
medication alongside
VPA)
3 126 Retrospective Psychiatric
patients
Rate of Hematologic
side effects during
VPA treatment
11–138
Increased risk
[80
5%
Martı´nez-Lazcano
et al. [7]
(concomitant
psychiatric
medication as well as
VPA)
3 167 Cross-sectional Psychiatric
patients
Frequency of use of
VPA in psychiatric
patients and rate of
relative side effects
72b 18%
Zighetti et al. [16] 3 20 cases,
20
controls
Cross-sectional Epilepsy Measurement of
parameters of
primary hemostasis
in VPA-treated
patients
67c 10% cases (subjects
treated with VPA)
20% controls
(healthy subjects
or treated with a
different
antiepileptic)
Quality rating was performed according to the following criteria (Qualitative Assessment Tool for Quantitative Studies): (i) selection bias (sample size
power and number of subjects who agreed to participate into the study); (ii) study design (randomized versus non-randomized trials); (iii) confounders
(yes/no); (iv) blinding (yes/no); (v) data collection methods (self-reported data, observations by investigators or medical records); (vi) presence of
description of numbers and reasons for withdrawals and drop-outs. 1 = strong (no weak ratings according to above criteria); 2 = moderate (one weak
rating according to above criteria); 3 = weak (two or more weak ratings according to above criteria)
NA not available, VPA valproic acid
aIn this study, patients received polytherapy (valproate plus antidepressants, clozapine, donepezil, aspirin, carbamazepine, heparin, ticlopidine,
trimethoprim-sulfamethoxazole). Among patients in treatment with valproate, subjects with thrombocytopenia more frequently received concomitant
treatment with aspirin and donepezil
bMean plasma concentrations (SD ± 20)
cMean plasma concentrations (SD ± 38)
dSignificant decrease of platelet count in bipolar subjects in treatment with valproate than in healthy controls
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study by Zighetti and colleagues [16] failed to find a sig-
nificant association between chronic VPA treatment and
risk of abnormal hemostasis or thrombocytopenia
(Table 1).
4 Conclusions
VPA is currently considered a first-line treatment option
for the management of both BD and different forms of
epilepsy in the light of its efficacy and relative safety. More
than 40 years of clinical experience have clearly estab-
lished the common adverse events associated with VPA,
including hepatotoxicity and the teratogenic risks. It is very
surprising that thrombocytopenia, although considered a
common/very common side effect according to the defi-
nition by the World Health Organization, has attracted less
interest in clinical research despite the important thera-
peutic implications. Of note, the available data report a
prevalence of thrombocytopenia between 5–54% of total
patients receiving treatment with VPA (12–18% in studies
with a sample size[150). The risk factors of VPA-asso-
ciated thrombocytopenia appear to be advanced age,
female gender, and high doses, so clinicians should be
particularly cautious in prescribing this compound in
elderly female patients, especially in doses [1 g/day. It
should also be remembered that elderly patients frequently
receive multiple therapies that can increase the risk of
thrombocytopenia or bleeding (e.g., aspirin or anticoagu-
lants frequently prescribed to the geriatric population).
Adjustment of doses seems to partially reverse VPA-as-
sociated thrombocytopenia.
Future research should address a number of questions.
First, the real clinical risks of VPA-associated thrombo-
cytopenia are unclear; for example, it is not defined whe-
ther VPA-associated thrombocytopenia is really associated
with an increased risk of life-threatening adverse events
such as hemorrhagic stroke. Second, although one study
demonstrated similar pharmacokinetic parameters in
epileptic and psychiatric patients in the course of VPA
therapy [17], the type of illness may influence the risk of
adverse events associated with thrombocytopenia. Patients
with BD, independently from treatment with atypical
antipsychotics, have a higher frequency of diabetes and
metabolic syndrome than the general population [2], so
treatment with VPA may expose bipolar subjects to a
further risk of cardiovascular events as a result of throm-
bocytopenia. Furthermore, patients with a psychiatric dis-
order are frequently treated with multiple therapies which
may increase the risk of bleeding (e.g., selective serotonin
reuptake inhibitors). Third, it is not entirely clear how soon
hematological abnormalities may appear, so that short-term
therapy (such as during a manic episode) may have a
limited effect compared with chronic prophylaxis [14].
Also, a different pharmacological formulation (intravenous
versus oral) may impact differently on the risk of throm-
bocytopenia. Finally, the exact mechanism of valproate-
associated thrombocytopenia should be clarified with the
aim to carry out preventive strategies for this adverse event
as well as to identify high-risk populations.
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